Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
47
DAWN Quote, Financials, Valuation and Earnings
Last price:
$8.35
Seasonality move
:
-5.26%
Day range:
$8.21 - $8.60
52-week range:
$5.64 - $13.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.40x
P/B ratio:
1.90x
Volume:
2.1M
Avg. volume:
2.8M
1-year change:
-39.57%
Market cap:
$856.3M
Revenue:
$131.2M
EPS (TTM):
-$1.49
Analysts' Opinion
-
Consensus RatingDay One Biopharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.25, Day One Biopharmaceuticals, Inc. has an estimated upside of 166.79% from its current price of $8.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $8.34.
Fair Value
-
According to the consensus of 6 analysts, Day One Biopharmaceuticals, Inc. has 166.79% upside to fair value with a price target of $22.25 per share.
DAWN vs. S&P 500
-
Over the past 5 trading days, Day One Biopharmaceuticals, Inc. has underperformed the S&P 500 by -11.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Day One Biopharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Day One Biopharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Day One Biopharmaceuticals, Inc. reported revenues of $39.8M.
Earnings Growth
-
Day One Biopharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Day One Biopharmaceuticals, Inc. reported earnings per share of -$0.19.
Enterprise value:
407.6M
EV / Invested capital:
0.90x
Price / LTM sales:
6.40x
EV / EBIT:
--
EV / Revenue:
3.05x
PEG ratio (5yr expected):
-0.12x
EV / Free cash flow:
-3.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$119.6M
Return On Assets:
-27.59%
Net Income Margin (TTM):
-113.53%
Return On Equity:
-30.98%
Return On Invested Capital:
-30.8%
Operating Margin:
-60.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $102M | $133.7M | $93.8M | $39.8M | |
| Gross Profit | -$460K | $99.4M | $119.6M | $92.2M | $35.3M | |
| Operating Income | -$189.3M | -$211.5M | -$165.6M | $29.6M | -$24.3M | |
| EBITDA | -$188.8M | -$210.1M | -$162.1M | $30.4M | -$23.3M | |
| Diluted EPS | -$2.28 | -$1.01 | -$1.49 | $0.38 | -$0.19 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $303.3M | $380.5M | $413.3M | $581M | $490M | |
| Total Assets | $303.8M | $381.9M | $414.2M | $600.8M | $513.8M | |
| Current Liabilities | $6M | $18.3M | $24.5M | $39.7M | $56.5M | |
| Total Liabilities | $6.1M | $18.8M | $24.6M | $45.3M | $62.9M | |
| Total Equity | $297.7M | $363.1M | $389.6M | $555.5M | $450.9M | |
| Total Debt | $267K | $514K | $77K | $2.5M | $2.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$140.8M | -$89.5M | -$119.6M | $50.8M | -$5.8M | |
| Cash From Investing | $95.8M | $69M | -$262.5M | -$67.7M | $13.5M | |
| Cash From Financing | $165.3M | $202M | $2.6M | $200.1M | -- | |
| Free Cash Flow | -$141M | -$107.3M | -$124.9M | $50M | -$5.8M | |
DAWN
Sector
Market Cap
$856.3M
$28.8M
Price % of 52-Week High
59.91%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-0.43%
-1.32%
1-Year Price Total Return
-39.57%
-20.64%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.88
200-day SMA
Buy
Level
$7.48
Bollinger Bands (100)
Buy
Level
6.51 - 8.41
Chaikin Money Flow
Sell
Level
-21.9M
20-day SMA
Sell
Level
$9.05
Relative Strength Index (RSI14)
Sell
Level
46.94
ADX Line
Buy
Level
27.35
Williams %R
Buy
Level
-88.785
50-day SMA
Buy
Level
$8.03
MACD (12, 26)
Buy
Level
0.14
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
58M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.2745)
Sell
CA Score
(Annual)
Level (-0.6302)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.4613)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.
Stock Forecast FAQ
In the current month, DAWN has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The DAWN average analyst price target in the past 3 months is $22.25.
-
Where Will Day One Biopharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Day One Biopharmaceuticals, Inc. share price will rise to $22.25 per share over the next 12 months.
-
What Do Analysts Say About Day One Biopharmaceuticals, Inc.?
Analysts are divided on their view about Day One Biopharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Day One Biopharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Day One Biopharmaceuticals, Inc.'s Price Target?
The price target for Day One Biopharmaceuticals, Inc. over the next 1-year time period is forecast to be $22.25 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DAWN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Day One Biopharmaceuticals, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DAWN?
You can purchase shares of Day One Biopharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Day One Biopharmaceuticals, Inc. shares.
-
What Is The Day One Biopharmaceuticals, Inc. Share Price Today?
Day One Biopharmaceuticals, Inc. was last trading at $8.35 per share. This represents the most recent stock quote for Day One Biopharmaceuticals, Inc.. Yesterday, Day One Biopharmaceuticals, Inc. closed at $8.34 per share.
-
How To Buy Day One Biopharmaceuticals, Inc. Stock Online?
In order to purchase Day One Biopharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DAWN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DAWN
Sector
P/E ratio
--
23.71x
PEG ratio
-0.12x
-0.01x
P/B ratio
1.90x
1.84x
Price / LTM sales
6.40x
1.60x
Growth Metrics
DAWN
Sector
Revenue growth
-57.56%
4.85%
Earnings growth
-149.94%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.28
-$0.20
Profitability
DAWN
Sector
Profitability FY 2024
$125.9M
$3.6M
Return on invested capital
-30.8%
-30.98%
Return on assets
-27.59%
-27.62%
Return on equity
-30.98%
-36.69%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
DAWN
Sector
Total cash
$451.6M
$27.2M
Short term investments
$406.8M
$25.7M
Total assets
$582.8M
$79.7M
Long term debt
$2.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
